跳至主要内容
临床试验/IRCT20211110053031N1
IRCT20211110053031N1尚未招募2 期

Evaluation and comparison of efficacy of atropine eye drops and ipratropium bromide oral spray and amitriptyline tablet in the management of clozapine-induced sialorrhea in patients with refractory schizophrenia using the TNHS(Toronto Nocturnal in the management of clozapine-induced sialorrhea in patients with refractory schizophrenia using the TNHS(Toronto Nocturnal Hypersalivation) scale Hypersalivation) scale

Shiraz University of Medical Sciences0 个研究点目标入组 1 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
1

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Patients aged 18 to 65 years with a diagnosis of schizophrenia according to the DSM-V criteria
  • Patients should be receiving clozapine for at least 30 days
  • Patients should have a minimum score of 2 on the TNHS scale for sialorrhea

排除标准

  • Development of allergies or history of allergies to amitriptyline, atropine and ipratropium bromide
  • Has an underlying disease such as Parkinson's or cerebral palsy that causes sialorrhea
  • The patient has problems and comorbidities such as untreated constipation or urinary retention or bladder obstruction
  • Concomitant use of drugs such as tricyclic antidepressants and atropine and ipratropium bromide and other anticholinergic drugs
  • Breastfeeding and pregnancy
  • History of diseases such as myasthenia gravis, seizures, cardiac arrhythmias, glaucoma, pyloric obstruction, prostate hypertrophy, renal failure, severe autonomic dysfunction, mental retardation, and paralytic paralysis

研究者

相似试验